PsiOxus Therapeutics Limited

40 articles about PsiOxus Therapeutics Limited

• PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

  8/11/2022

  PsiOxus Therapeutics, Ltd. today announces the appointment of Howard Davis, Ph.D., as Chief Executive Officer.

• 

  Novel CAR T Therapies Help Celyad's CMO Bring Hope to Fearful Patients

  9/29/2021

  Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.

• PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T‑SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

  9/15/2021

  PsiOxus Therapeutics, Ltd. (PsiOxus), a tumor re-engineering company, today announced that they will present key safety and translational data from their first-in-human phase 1 FORTITUDE clinical study at the European Society for Medical Oncology (ESMO) Congress 2021 this week.

• PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

  4/14/2021

  PsiOxus Therapeutics, Ltd., a clinical stage oncology company ​re-programming ​the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. presented preclinical data at the American Association for Cancer Research Annual Meeting 2021.

• PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration

  4/7/2021

  PsiOxus Therapeutics, Ltd. announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® to treat a range of tumor types in late-stage cancer patients.

• PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer

  3/5/2020

  PsiOxus® Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy, to cancer patients.

• PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors

  11/15/2018

  This pre-clinical immuno-oncology research will utilize PsiOxus' proprietary T-SIGn platform.

• 

  BioSpace Movers and Shakers for Oct. 15

  10/15/2018

  Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
• 

  Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutics for $245 Million

  9/13/2018

  Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.

• Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors

  6/7/2018

  Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.

• PsiOxus Therapeutics Receives $15M Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

  12/12/2017

  Under the terms of the December 2016 agreement, Bristol-Myers Squibb granted PsiOxus an upfront payment of $50 million.

• PsiOxus Announce Two New Board Appointments: New Board Appointments Strengthen Company’s U.S. Presence

  8/17/2017

• Hiring Underway at PsiOxus' New Facility in Philadelphia

  6/14/2017

• Imperial Innovations Release: Portfolio Company PsiOxus Signs Exclusive Worldwide License Agreement With BMS For NG-348 Its First "Armed" Oncolytic Virus

  12/20/2016

• Bristol-Myers Squibb Inks $936 Million “Armed” Oncolytic Virus Deal With PsiOxus

  12/20/2016

• UK's PsiOxus Appoints Two New Execs in the U.S. in C-Suite Shakeup

  9/16/2016

• PsiOxus Gets Upfront $10 Million, Ties Immuno-Oncology Clinical Pact With Bristol-Myers Squibb

  6/30/2016

• Parker Institute For Cancer Immunotherapy And PsiOxus Announce Intention To Collaborate On Tumor-Specific Immuno-Gene Therapy

  4/14/2016

• PsiOxus Initiates Combination Of Paclitaxel With Oncolytic Virus Enadenotucirev In Ovarian Cancer Study

  3/10/2016